Benzoselenophene compounds, pharmaceutical compositions containing the same, and antibody-drug conjugates

By introducing new water-soluble groups into benzosenophen, high-activity and water-soluble benzosenophen derivatives are prepared, which solves the problem of water solubility limitation of antibody-drug conjugates and achieves high efficiency for specific cancers Improved treatment effect and stability.

CN115038699BActive Publication Date: 2024-12-03AIMED BIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202180012034.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-01-30
Filing Date
2021-01-27
Publication Date
2024-12-03
Estimated Expiration
2041-01-27

AI Technical Summary

Technical Problem

Existing antibody-drug conjugates have limitations in water solubility, making it difficult to synthesize stable pharmaceutical compositions, affecting their targeted delivery and stability in vivo.

Method used

By introducing new water-soluble groups into benzoselenophene, water-soluble and highly active benzoselenophene derivatives are prepared for preparation of antibody-drug conjugates and combining them with proteins, nanoparticles, etc. to improve the Its stability and targeting in vivo.

Benefits of technology

It has achieved efficient anti-cancer effects on cancer cells, especially in brain cancer, brain metastases, non-small cell lung cancer and melanoma, which has significantly improved the therapeutic effect, and improved the water solubility and stability of the drug, which has enhanced its Potential for application as prodrug and antibody-drug conjugates.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115038699B_ABST
    Figure CN115038699B_ABST
Patent Text Reader

Abstract

The present disclosure relates to benzoselenophene compounds, methods for preparing benzoselenophene compounds, pharmaceutical compositions comprising benzoselenophene compounds, and antibody-drug conjugates.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to benzoselenophene compounds, methods for preparing benzoselenophene compounds, and pharmaceutical compositions and antibody-drug conjugates comprising the benzoselenophene compounds. Background Art

[0002] Dulocamycin is known as a highly effective anticancer agent. However, duocarmycin may produce toxins to normal cells and kill experimental animals during animal experiments. Therefore, duocarmycin itself cannot be used in humans. In this regard, research has been actively conducted to kill only tumor cells through tumor cell-specific reactions and maintain stability and high activity in the blood.

[0003] Antibody therapy has been used to target and treat patients with cancer, immunological disorders and angiogenesis disorders. When antibody-drug conjugates (ADCs) (i.e., immunoconjugates) are used to locally deliver drugs (e.g., cytotoxic agents or cell proliferation inhibitors) that kill or inhibit tumor cells during cancer treatment [references: Payne, G. (2003) Cancer Cell 3: 207-212; Trail et al. (2003) Cancer Immunol. Immunother. 52: 328-337; Syrigos and Epenetos (1999) Anticancer Research 19: 605-614; Niculescu-Duvaz and Springer (1997) Adv. Drug Del. Rev. 26: 151-172; US 4975278], in theory, drugs can be targeted and delivered to tumor cells and allowed to accumulate in tumor cells.

[0004] However, conventional derivatives with excellent activities are limited in water solubility and thus may aggregate when bound to target-specific proteins such as antibodies, which makes it difficult to synthesize stable antibody-drug conjugates. Summary of the invention

[0005] Technical issues

[0006] The present disclosure contemplates providing benzoselenophene compounds, methods for preparing benzoselenophene compounds, and pharmaceutical compositions and antibody-drug conjugates comprising the benzoselenophene compounds.

[0007] Specifically, the present disclosure relates to the preparation of novel benzoselenophene derivatives with increased water solubility and activity by introducing novel water-soluble groups into benzoselenophene, and the use of benzoselenophene derivatives as anticancer drugs. The novel water-soluble benzoselenophene derivatives disclosed herein can be used as antibody-drug conjugates and can be used as prodrugs. In addition, the water-soluble benzoselenophene derivatives can be fused with target-specific substances such as proteins, ligands, nanoparticles and aptamers, which allows them to be used as prodrugs.

[0008] However, the problems to be solved by the present disclosure are not limited to the above problems. Although not described herein, those skilled in the art can clearly understand other problems to be solved by the present disclosure through the following description.

[0009] Technical Solution

[0010] According to the first aspect of the present disclosure, a benzoselenophene compound is provided, which is represented by the following chemical formula I:

[0011] [Chemical formula 1]

[0012]

[0013] In the above chemical formula 1,

[0014] R 1 is substituted or unsubstituted C 3-10 Heterocycloalkyl, substituted or unsubstituted C 5-10 Aryl, substituted or unsubstituted C 3-10 Heteroaryl,

[0015] R 2 and R 3 are each independently hydrogen, fluorine, chlorine, bromine, iodine or substituted or unsubstituted C 1-5 alkyl,

[0016] R 4 and R 5 are each independently hydrogen, or substituted or unsubstituted C 1-5 alkyl,

[0017] The heterocycloalkyl group and the heteroaryl group contain at least one heteroatom selected from N, O and S, and

[0018] X is halogen.

[0019] According to a second aspect of the present disclosure, there is provided a method for preparing a benzoselenophene-based compound, comprising: (a) reacting a carboxylic acid represented by the following chemical formula 2 with an amine represented by the following chemical formula 3 to prepare an intermediate product; and (b) reacting the intermediate product with an amine represented by the following chemical formula 4 to obtain a benzoselenophene-based compound represented by the following chemical formula 1:

[0020] [Chemical formula 1]

[0021]

[0022] [Chemical formula 2]

[0023]

[0024] [Chemical formula 3]

[0025]

[0026] [Chemical formula 4]

[0027]

[0028] In the above Chemical Formula 1, Chemical Formula 2, Chemical Formula 3 and Chemical Formula 4,

[0029] R 1 is substituted or unsubstituted C 3-10 Heterocycloalkyl, substituted or unsubstituted C 5-10 Aryl, substituted or unsubstituted C 3-10 Heteroaryl,

[0030] R 2 and R 3 are each independently hydrogen, fluorine, chlorine, bromine, iodine or substituted or unsubstituted C 1-5 alkyl,

[0031] R 4 and R 5 are each independently hydrogen, or substituted or unsubstituted C 1-5 alkyl,

[0032] R 6 is substituted or unsubstituted C 1-5 alkyl,

[0033] The heterocycloalkyl group and the heteroaryl group contain at least one heteroatom selected from N, O and S, and

[0034] X is halogen.

[0035] According to a third aspect of the present invention, a pharmaceutical composition is provided, comprising a benzoselenophene compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof, and the pharmaceutical composition is used for preventing or treating a proliferative disease:

[0036] [Chemical formula 1]

[0037]

[0038] In the above chemical formula 1,

[0039] R1 is substituted or unsubstituted C 3-10 Heterocycloalkyl, substituted or unsubstituted C 5-10 Aryl, substituted or unsubstituted C 3-10 Heteroaryl,

[0040] R 2 and R 3 are each independently hydrogen, fluorine, chlorine, bromine, iodine or substituted or unsubstituted C 1-5 alkyl,

[0041] R 4 and R 5 are each independently hydrogen, or substituted or unsubstituted C 1-5 alkyl,

[0042] The heterocycloalkyl group and the heteroaryl group contain at least one heteroatom selected from N, O and S, and

[0043] X is halogen.

[0044] According to a fourth aspect of the present disclosure, an antibody-drug conjugate or a pharmaceutically acceptable salt thereof is provided, comprising an antibody; a linker; and a benzoselenophene compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof:

[0045] [Chemical formula 1]

[0046]

[0047] In the above chemical formula 1,

[0048] R 1 is substituted or unsubstituted C 3-10 Heterocycloalkyl, substituted or unsubstituted C 5-10 Aryl, substituted or unsubstituted C 3-10 Heteroaryl,

[0049] R 2 and R 3 are each independently hydrogen, fluorine, chlorine, bromine, iodine or substituted or unsubstituted C 1-5 alkyl,

[0050] R 4 and R 5 are each independently hydrogen, or substituted or unsubstituted C 1-5 alkyl,

[0051] The heterocycloalkyl group and the heteroaryl group contain at least one heteroatom selected from N, O and S, and

[0052] X is halogen.

[0053] According to a fifth aspect of the present disclosure, an anticancer composition is provided, comprising the antibody-drug conjugate according to the fourth aspect or a pharmaceutically acceptable salt thereof.

[0054] Beneficial Effects

[0055] According to the embodiments of the present disclosure, by introducing a novel water-soluble group, a novel benzoselenophene derivative with greatly increased water solubility and activity can be prepared, and the benzoselenophene derivative can be used as an anticancer drug. The novel water-soluble benzoselenophene derivative disclosed herein can be used as an antibody-drug conjugate and can be used as a prodrug. In addition, the water-soluble benzoselenophene derivative can be fused with target-specific substances such as proteins, ligands, nanoparticles and aptamers, which makes it possible to use it as a prodrug.

[0056] According to the embodiment of the present invention, benzoselenol compounds are substances with high anticancer effect on cancer cells. 50 In the nM or pM range, and can be used for new drug development using antibody-drug conjugates.

[0057] The benzoselenophene compounds according to the embodiments of the present disclosure, as well as the pharmaceutical compositions and antibody-drug conjugates containing the benzoselenophene compounds, have significant therapeutic effects on cancer, and particularly have excellent anti-cancer and therapeutic effects on brain cancer, brain metastases, non-small cell lung cancer and melanoma.

[0058] According to the embodiments of the present disclosure, a DNA alkylation derivative including a benzoselenophene-based compound having excellent water solubility and activity can be synthesized and used as an anticancer drug or a precursor thereof.

[0059] The benzoselenophene compound derivative according to the embodiments of the present disclosure can be combined with an antibody-drug conjugate or a protein-conjugate to act on a target in a target-directed manner, thereby having a selective effect through specific treatment.

[0060] The benzoselenophene derivatives (precursors, prodrugs), benzoselenophene derivative-linkers and benzoselenophene derivative-linker-ligand conjugates according to the embodiments of the present disclosure are stable per se, but can be used to target proliferative diseases such as cancer (particularly, brain cancer, brain metastases, melanoma, non-small cell lung cancer), specific treatments and / or maximize drug efficacy. Therefore, they have industrial applicability. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 The SEC analysis results of Trastuzumab-glucuronide Compound 3 ADC prepared according to an embodiment of the present disclosure are shown.

[0062] Figure 2The results of HIC analysis of Trastuzumab-glucuronide Compound 3 ADC prepared according to an embodiment of the present disclosure are shown.

[0063] Figure 3 The PLRP analysis results of the trastuzumab-glucuronide compound 3 ADC prepared according to an embodiment of the present disclosure are shown.

[0064] Figure 4 is a table showing the results of analysis of in vitro cell line activity of Compound 3 prepared according to Examples of the present disclosure.

[0065] Figure 5 Shown is a graph of analysis of in vivo cell line activity of Compound 3 (DS-24) prepared according to examples of the present disclosure.

[0066] Figure 6 The analysis results of the correlation between compound 3 prepared according to the examples of the present disclosure and the corresponding cancer types in NCI cell lines are shown.

[0067] Figure 7a is a graph showing nonlinear regression analysis of the dose-response curves of cell viability of MCF-7 and NCI-N87 cells treated with ADC (DS-24), Figure 7b As a result, the IC 50 Value data.

[0068] Figure 8a It is a device used to confirm the inhibitory effect of ADC (DS-24) on BT474 tumor spheroids. Figure 8b is a graph showing nonlinear regression analysis of dose-response curves, Figure 8c As a result, the IC 50 Value data.

[0069] Figure 9a and Figure 9b Data on the anticancer effect of ADC (DS-24) in the NCI-N87 xenograft animal model and the body weight change of nude mice administered with ADC (DS-24) are shown, respectively.

[0070] Fig.10a and Fig.10b Inflammatory cell counts and anemia-related values ​​according to toxicity analysis by complete blood count (CBC) assay for ADC (DS-24) in the NCI-N87 xenograft animal model are shown, respectively.

[0071] Fig.11a , Fig.11b and Fig.11cShown are data demonstrating the cell viability inhibitory effects of seven types of payloads except Compound 3 (DS-24) on glioblastoma cell line U87MG, multiple myeloma cell line KMS11, and bladder cancer cell line RT112, respectively.

[0072] Fig.12a , Figure 12b , Fig.12c , Fig.12d , Fig.12e and Fig.12f Data demonstrating the cell viability inhibitory effects of seven types of payloads except Compound 3 (DS-24) on six types of cells derived from patients with glioblastoma are shown separately.

[0073] Fig.13a and Fig.13b are graphs showing cell viability of NCI-N87 depending on the concentrations of DS-24 and DS-26, respectively.

[0074] Fig.14a and Fig.14b are graphs showing cell viability of SK-OV3 depending on the concentrations of DS-24 and DS-26, respectively. DETAILED DESCRIPTION

[0075] Hereinafter, embodiments of the present disclosure will be described in detail with reference to the accompanying drawings so that those skilled in the art can easily implement the present disclosure. However, it should be noted that the present disclosure is not limited to these embodiments, but can be implemented in various other ways. In the accompanying drawings, for simplicity of explanation, parts not related to the description are omitted, and the same reference numerals represent the same parts throughout the document.

[0076] Throughout the document, the terms “connected to” or “coupled to” used to indicate that one element is connected or coupled to another element include the case where one element is “directly connected or coupled to” another element and the case where one element is “electronically connected or coupled to” another element through another element.

[0077] Throughout the document, the term “on” used to indicate the position of one element relative to another element includes the case where one element is adjacent to the other element and the case where any other elements are present between the two elements.

[0078] In addition, throughout the document, the terms "comprise or include" and / or "comprising or including" used in the document mean that in addition to the described components, steps, operations and / or elements, it does not exclude the existence or addition of one or more other components, steps, operations and / or elements, unless the context indicates otherwise.

[0079] Throughout the document, the term "about or approximately" or "substantially" is intended to have the meaning of being close to a specified numerical value or range within a permissible error, and is intended to prevent the exact or absolute numerical values ​​disclosed for understanding the present disclosure from being illegally or unfairly used by any unconscionable third party.

[0080] Throughout this document, the term "step of" does not mean "step for".

[0081] Throughout this document, the term “combination” included in a Markush-type description means a mixture or combination of one or more components, steps, operations and / or elements selected from the group consisting of components, steps, operations and / or elements described in a Markush-type manner, thus meaning that the present disclosure includes one or more components, steps, operations and / or elements selected from the Markush group.

[0082] Throughout this document, phrases in the form "A and / or B" mean "A or B, or A and B."

[0083] Throughout this document, the term "alkyl" includes straight or branched chain alkyl groups having 1 to 12 carbon atoms, 1 to 10 carbon atoms, 1 to 8 carbon atoms, 1 to 5 carbon atoms, or 1 to 4 carbon atoms, and all possible isomers thereof. For example, alkyl groups may include methyl (Me), ethyl (Et), n-propyl ( n Pr), isopropyl ( i Pr), n-butyl ( n Bu), tert-butyl ( t Bu), isobutyl ( i Bu), sec-butyl ( s Bu), pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl and isomers thereof, but may not be limited thereto.

[0084] In the following description, exemplary embodiments of the present disclosure will be described in detail, but the present disclosure may not be limited thereto.

[0085] According to a first aspect of the present disclosure, a benzoselenophene-based compound is provided, which is represented by the following Chemical Formula 1:

[0086] [Chemical formula 1]

[0087]

[0088] In the above chemical formula 1,

[0089] R 1 is substituted or unsubstituted C 3-10 Heterocycloalkyl, substituted or unsubstituted C 5-10Aryl, substituted or unsubstituted C 3-10 Heteroaryl,

[0090] R 2 and R 3 are each independently hydrogen, fluorine, chlorine, bromine, iodine or substituted or unsubstituted C 1-5 alkyl,

[0091] R 4 and R 5 are each independently hydrogen, or substituted or unsubstituted C 1-5 alkyl,

[0092] The heterocycloalkyl group and the heteroaryl group contain at least one heteroatom selected from N, O and S, and

[0093] X is halogen.

[0094] In one embodiment of the present disclosure, if the functional group is substituted, the substituent may include one or more members selected from the group consisting of an acyl group, an amino group (including an amino group, a monoalkylamino group and a dialkylamino group, a monoarylamino group and a diarylamino group, and an alkylarylamino group), an acylamino group (including a carbamoyl group and a urea group), an alkylcarbonyloxy group, an arylcarbonyloxy group, an alkoxycarbonyloxy group, an alkoxycarbonyl group, a carboxyl group, a carboxylate group, an aminocarbonyl group, a monoalkylaminocarbonyl group and a dialkylaminocarbonyl group, a cyano group, an azido group, a halogen group, a hydroxyl group, , nitro, trifluoromethyl, thiol, alkylthiol, arylthiol, alkylthiocarbonyl, thiocarboxylate, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, lower alkoxy, aryloxy, aryloxycarbonyloxy, benzyloxy, benzyl, sulfinyl, alkylsulfinyl, sulfonyl, sulfate, sulfonate, sulfonamide, phosphate, phosphonate, phosphinate, oxo, guanidino, imino and formyl, but may not be limited thereto.

[0095] In one embodiment of the present disclosure, R 1 may include a C 3-10 Heterocycloalkyl or C 3-10 heteroaryl, and R 4 and R 5 Each may be independently hydrogen, methyl or ethyl, but is not limited thereto.

[0096] In one embodiment of the present disclosure, X may be F, Cl, Br or I, but may not be limited thereto. In addition, in one embodiment of the present disclosure, X may be Cl.

[0097] In one embodiment of the present disclosure, the benzoselenophene-based compounds of the present disclosure are in the -CHR 2 CHR1 R 3 Contains two sp 3 The carbon atoms (which are connected to the benzoselenophene main body through an amide bond) serve as the main framework, thus increasing the flexibility of the molecule itself. In addition, ideally, R 1 Various derivatives may include pentagonal or hexagonal rings containing N, O or S. In addition, R 1 Bicyclic rings with or without heteroatoms may be included, which may promote DNA minor groove binding in anticancer mechanisms.

[0098] In one embodiment of the present disclosure, R 1 Can include pyrrolidinyl (-NC4H8), piperidinyl (-NC5H 10 ), piperazinyl (-N2C4H9), 4-methylpiperazin-1-yl (-N2C5H 11 ), morpholino (-NOC4H8), Y may include -CH2- or -C2H4-, Z may include -CHR-, -NR, -O- or -S-, and R may include hydrogen or C 1-3 Alkyl, but may not be limited thereto.

[0099] In one embodiment of the present disclosure, R 1 It can be pyrrolidinyl (-NC4H8), piperidinyl (-NC5H 10 ), piperazinyl (-N2C4H9), 4-methylpiperazin-1-yl (-N2C5H 11 ) or morpholino (-NOC4H8).

[0100] In one embodiment of the present disclosure, R 2 and R 3 Both can be hydrogen.

[0101] In one embodiment of the present disclosure, R 5 and R 6 Each may independently be hydrogen, methyl, ethyl or propyl.

[0102] In one embodiment of the present disclosure, the benzoselenophene-based compound may include the following:

[0103] [Compound 3]

[0104] or

[0105] [Compound 4]

[0106]

[0107] According to a second aspect of the present disclosure, a method for preparing a benzoselenophene compound is provided, comprising: (a) reacting a carboxylic acid represented by the following chemical formula 2 with an amine represented by the following chemical formula 3 to prepare an intermediate product; (b) reacting the intermediate product with an amine represented by the following chemical formula 4 to obtain a benzoselenophene compound represented by the following chemical formula 1:

[0108] [Chemical formula 1]

[0109]

[0110] [Chemical formula 2]

[0111]

[0112] [Chemical formula 3]

[0113]

[0114] [Chemical formula 4]

[0115]

[0116] In the above Chemical Formula 1, Chemical Formula 2, Chemical Formula 3 and Chemical Formula 4,

[0117] R 1 is substituted or unsubstituted C 3-10 Heterocycloalkyl, substituted or unsubstituted C 5-10 Aryl, substituted or unsubstituted C 3-10 Heteroaryl,

[0118] R 2 and R 3 are each independently hydrogen, fluorine, chlorine, bromine, iodine or substituted or unsubstituted C 1-5 alkyl,

[0119] R 4 and R 5 are each independently hydrogen, or substituted or unsubstituted C 1-5 alkyl,

[0120] R 6 is substituted or unsubstituted C 1-5 alkyl,

[0121] The heterocycloalkyl group and the heteroaryl group contain at least one heteroatom selected from N, O and S, and

[0122] X is halogen.

[0123] Detailed descriptions on the second aspect of the present disclosure that overlap with those on the first aspect of the present disclosure are omitted hereinafter, but the descriptions of the first aspect of the present disclosure may be identically applied to the second aspect of the present disclosure even though they are omitted hereinafter.

[0124] In one embodiment of the present disclosure, if the functional group is substituted, the substituent may include one or more members selected from the group consisting of acyl, amino (including amino, monoalkylamino and dialkylamino, monoarylamino and diarylamino, and alkylarylamino), acylamino (including carbamoyl and ureido), alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, alkoxycarbonyl, carboxyl, carboxylate, aminocarbonyl, monoalkylaminocarbonyl and dialkylaminocarbonyl, cyano, azido, halogen, alkylamino ... The invention also includes a halogen group, a hydroxyl group, a nitro group, a trifluoromethyl group, a thiol group, an alkylthiol group, an arylthiol group, an alkylthiocarbonyl group, a thiocarboxylate group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, a lower alkoxy group, an aryloxy group, an aryloxycarbonyloxy group, a benzyloxy group, a benzyl group, a sulfinyl group, an alkylsulfinyl group, a sulfonyl group, a sulfate group, a sulfonate group, a sulfonamide group, a phosphate group, a phosphonate group, a phosphinate group, an oxo group, a guanidinyl group, an imino group, and a formyl group, but may not be limited thereto.

[0125] In one embodiment of the present disclosure, R 1 may include a C 3-10 Heterocycloalkyl or C 3-10 heteroaryl, and R 4 and R 5 Each may be independently hydrogen, methyl or ethyl, but is not limited thereto.

[0126] In one embodiment of the present disclosure, X may be F, Cl, Br or I, but may not be limited thereto. In addition, in one embodiment of the present disclosure, X may be Cl.

[0127] In one embodiment of the present disclosure, the benzoselenophene-based compounds of the present disclosure are in the -CHR 2 CHR 1 R 3 Contains two sp 3 The carbon atoms (which are connected to the benzoselenophene main body through an amide bond) serve as the main framework, thus increasing the flexibility of the molecule itself. In addition, ideally, R 1 Various derivatives may include pentagonal or hexagonal rings containing N, O or S. In addition, R 1 Bicyclic rings with or without heteroatoms may be included, which may promote DNA minor groove binding in anticancer mechanisms.

[0128] In one embodiment of the present disclosure, R1 Can include pyrrolidinyl (-NC4H8), piperidinyl (-NC5H 10 ), piperazinyl (-N2C4H9), 4-methylpiperazin-1-yl (-N2C5H 11 ), morpholino (-NOC4H8), Y may include -CH2- or -C2H4-, Z may include -CHR-, -NR, -O- or -S-, and R may include hydrogen or C 1-3 Alkyl, but may not be limited thereto.

[0129] In one embodiment of the present disclosure, R 1 It can be pyrrolidinyl (-NC4H8), piperidinyl (-NC5H 10 ), piperazinyl (-N2C4H9), 4-methylpiperazin-1-yl (-N2C5H 11 ) or morpholino (-NOC4H8).

[0130] In one embodiment of the present disclosure, R 2 and R 3 Both can be hydrogen.

[0131] In one embodiment of the present disclosure, R 5 and R 6 Each may independently be hydrogen, methyl, ethyl or propyl.

[0132] In one embodiment of the present disclosure, the intermediate product produced by (a) may be in the form of a carboxylic acid or a carboxylate salt, because by adjusting the pH to make R 6 is replaced by hydrogen, but may not be limited thereto.

[0133] In one embodiment of the present disclosure, the amine compound represented by the above Chemical Formula 4 may be obtained by acid-treating a conventionally known seco-MCBI as shown below, but may not be limited thereto:

[0134]

[0135] In one embodiment of the present disclosure, the benzoselenophene-based compound may include the following:

[0136] [Compound 3]

[0137] or

[0138] [Compound 4]

[0139]

[0140] According to a third aspect of the present invention, a pharmaceutical composition is provided, comprising a benzoselenophene compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof, and the pharmaceutical composition is used for preventing or treating a proliferative disease:

[0141] [Chemical formula 1]

[0142]

[0143] In the above chemical formula 1,

[0144] R 1 is substituted or unsubstituted C 3-10 Heterocycloalkyl, substituted or unsubstituted C 5-10 Aryl, substituted or unsubstituted C 3-10 Heteroaryl,

[0145] R 2 and R 3 are each independently hydrogen, fluorine, chlorine, bromine, iodine or substituted or unsubstituted C 1-5 alkyl,

[0146] R 4 and R 5 are each independently hydrogen, or substituted or unsubstituted C 1-5 alkyl,

[0147] The heterocycloalkyl group and the heteroaryl group contain at least one heteroatom selected from N, O and S, and

[0148] X is halogen.

[0149] Detailed descriptions about the third aspect of the present disclosure that overlap with those about the first and second aspects of the present disclosure are omitted below, but the descriptions of the first and second aspects of the present disclosure may be applied identically to the third aspect of the present disclosure, although they are omitted below.

[0150] In one embodiment of the present disclosure, the benzoselenophene-based compound or a pharmaceutically acceptable salt thereof may be a prodrug, but may not be limited thereto.

[0151] In one embodiment of the present disclosure, the benzoselenophene-based compound or a pharmaceutically acceptable salt thereof may be in an active form when present in a solvent or administered into the body, but may not be limited thereto.

[0152] In one embodiment of the present disclosure, the proliferative disease may include at least one selected from the group consisting of a neoplasm, a tumor, a cancer, a leukemia, a psoriasis, a bone disease, a fibroblast disorder, and atherosclerosis, but may not be limited thereto.

[0153] In one embodiment of the present disclosure, cancer may include at least one selected from the following: solid tumors, hematological malignancies, colorectal cancer, uterine cancer, uterine fibroids, meningioma, lung cancer, small cell lung cancer, non-small cell lung cancer, gastrointestinal malignancies, colorectal cancer, intestinal cancer, breast cancer, ovarian cancer, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, brain cancer, brain metastases, sarcoma, osteogenic sarcoma, Kaposi's sarcoma and melanoma, but may not be limited thereto. The pharmaceutical composition according to one embodiment of the present disclosure can be applied to various diseases as a target for prevention or treatment, not limited to cancer types.

[0154] In one embodiment of the present disclosure, if the functional group is substituted, the substituent may include one or more members selected from the group consisting of acyl, amino (including amino, monoalkylamino and dialkylamino, monoarylamino and diarylamino, and alkylarylamino), acylamino (including carbamoyl and ureido), alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, alkoxycarbonyl, carboxyl, carboxylate, aminocarbonyl, monoalkylaminocarbonyl and dialkylaminocarbonyl, cyano, azido, halogen, alkylamino ... The invention also includes a halogen group, a hydroxyl group, a nitro group, a trifluoromethyl group, a thiol group, an alkylthiol group, an arylthiol group, an alkylthiocarbonyl group, a thiocarboxylate group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, a lower alkoxy group, an aryloxy group, an aryloxycarbonyloxy group, a benzyloxy group, a benzyl group, a sulfinyl group, an alkylsulfinyl group, a sulfonyl group, a sulfate group, a sulfonate group, a sulfonamide group, a phosphate group, a phosphonate group, a phosphinate group, an oxo group, a guanidinyl group, an imino group, and a formyl group, but may not be limited thereto.

[0155] In one embodiment of the present disclosure, R 1 may include a C 3-10 Heterocycloalkyl or C 3-10 heteroaryl, and R 4 and R 5 Each may be independently hydrogen, methyl or ethyl, but is not limited thereto.

[0156] In one embodiment of the present disclosure, X may be F, Cl, Br or I, but may not be limited thereto. In addition, in one embodiment of the present disclosure, X may be Cl.

[0157] In one embodiment of the present disclosure, the benzoselenophene-based compounds of the present disclosure are in the -CHR 2 CHR 1 R 3 Contains two sp 3 The carbon atoms (which are connected to the benzoselenophene main body through an amide bond) serve as the main framework, thus increasing the flexibility of the molecule itself. In addition, ideally, R 1Various derivatives may include pentagonal or hexagonal rings containing N, O or S. In addition, R 1 Bicyclic rings with or without heteroatoms may be included, which may promote DNA minor groove binding in anticancer mechanisms.

[0158] In one embodiment of the present disclosure, R 1 Can include pyrrolidinyl (-NC4H8), piperidinyl (-NC5H 10 ), piperazinyl (-N2C4H9), 4-methylpiperazin-1-yl (-N2C5H 11 ), morpholino (-NOC4H8), Y may include -CH2- or -C2H4-, Z may include -CHR-, -NR, -O- or -S-, and R may include hydrogen or C 1-3 Alkyl, but may not be limited thereto.

[0159] In one embodiment of the present disclosure, R 1 It can be pyrrolidinyl (-NC4H8), piperidinyl (-NC5H 10 ), piperazinyl (-N2C4H9), 4-methylpiperazin-1-yl (-N2C5H 11 ) or morpholino (-NOC4H8).

[0160] In one embodiment of the present disclosure, R 2 and R 3 Both can be hydrogen.

[0161] In one embodiment of the present disclosure, R 5 and R 6 Each may independently be hydrogen, methyl, ethyl or propyl.

[0162] In one embodiment of the present disclosure, the benzoselenophene-based compound may include the following:

[0163] [Compound 3]

[0164]

[0165] [Compound 4]

[0166]

[0167] According to a fourth aspect of the present invention, an antibody-drug conjugate or a pharmaceutically acceptable salt thereof is provided, comprising an antibody, a linker and a benzoselenophene compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof:

[0168] [Chemical formula 1]

[0169]

[0170] In the above chemical formula 1,

[0171] R 1 is substituted or unsubstituted C 3-10 Heterocycloalkyl, substituted or unsubstituted C 5-10 Aryl, substituted or unsubstituted C 3-10 Heteroaryl,

[0172] R 2 and R 3 are each independently hydrogen, fluorine, chlorine, bromine, iodine or substituted or unsubstituted C 1-5 alkyl,

[0173] R 4 and R 5 are each independently hydrogen, or substituted or unsubstituted C 1-5 alkyl,

[0174] The heterocycloalkyl group and the heteroaryl group contain at least one heteroatom selected from N, O and S, and

[0175] X is halogen.

[0176] The detailed descriptions about the fourth aspect of the present disclosure that overlap with those about the first to third aspects of the present disclosure are omitted below, but the descriptions of the first to third aspects of the present disclosure can be applied identically to the fourth aspect of the present disclosure, although they are omitted below.

[0177] In one embodiment of the present disclosure, the antibody-drug conjugate or a pharmaceutically acceptable salt thereof may be a prodrug, but may not be limited thereto.

[0178] In one embodiment of the present disclosure, the antibody-drug conjugate or a pharmaceutically acceptable salt thereof may be in an active form when present in a solvent or administered into the body, but may not be limited thereto.

[0179] In one embodiment of the present disclosure, the antibody may include an antibody, an antibody variant, or an antigen-binding fragment thereof that is immunospecific for a proliferative disease, but may not be limited thereto. Here, the term "antibody" may include polyclonal antibodies and monoclonal antibodies, and ideally, it may be a monoclonal antibody and may have a complete antibody form. The whole antibody has two full-length light chains and two full-length heavy chains and includes an invariant domain, and each light chain is connected to a heavy chain by a disulfide bond. In addition, in one embodiment of the present disclosure, the antibody may include a monoclonal antibody, a multispecific antibody, a human antibody, a humanized antibody, a chimeric antibody, a short-chain Fvs (scFV), a short-chain antibody, a Fab fragment, a F(ab') fragment, a disulfide-bonded FV (dsFV), and an anti-idiotype (anti-Id) antibody or an epitope-binding fragment thereof, etc., but may not be limited thereto. The complete anti-c-Met antibody according to an embodiment of the present disclosure includes IgA, IgD, IgE, IgM, and IgG, and IgG includes IgG1, IgG2, IgG3, and IgG4 as its subtypes. In addition, the term "antibody variant" includes diabodies, and diabodies refer to antibodies that contain antibodies or antibody binding fragments for a single substance that recognize different antigens, respectively, and may include antibodies or antigen binding fragments thereof that have specificity for cancer-associated antigens or immune checkpoint protein antigens or specifically bind to immune effector cell-associated antigens, but may not be limited to a limited antibody framework. In addition, the term "antigen binding fragment" refers to a fragment that has the ability to specifically bind to an antigen, and may include Fab, Fab', F(ab')2, scFv (scFv)2, scFv-Fc, and Fv.

[0180] In one embodiment of the present disclosure, the proliferative disease may include at least one selected from the group consisting of a neoplasm, a tumor, a cancer, a leukemia, a psoriasis, a bone disease, a fibroblast disorder, and atherosclerosis, but may not be limited thereto.

[0181] In one embodiment of the present disclosure, cancer may include at least one selected from the following: solid tumors, hematological malignancies, colorectal cancer, uterine cancer, uterine fibroids, meningioma, lung cancer, small cell lung cancer, non-small cell lung cancer, gastrointestinal malignancies, colorectal cancer, intestinal cancer, breast cancer, ovarian cancer, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, brain cancer, brain metastases, sarcoma, osteogenic sarcoma, Kaposi's sarcoma and melanoma, but may not be limited thereto. The pharmaceutical composition according to one embodiment of the present disclosure can be applied to various diseases as a target for prevention or treatment, not limited to the type of cancer.

[0182] In one embodiment of the present disclosure, the antibody may bind to at least one tumor-associated antigen or cell surface receptor selected from the following, but may not be limited thereto. In addition, the antibody may bind to the following conventionally known antigens, but may not be limited thereto:

[0183] (1) BMPR1B (bone morphogenetic protein receptor type 1B); (2) E16 (LAT1, SLC7A5);

[0184] (3) STEAP1 (six-segment transmembrane epithelial antigen of the prostate); (4) 0772P (CA125, MUC16); (5) MPF (MPF, MSLN, SMR, megakaryocyte enhancer factor, mesothelin); (6) Napi3b [NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter (3b); (7) Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, armplate protein 5b H log, sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (armplate protein) 5B); (8) PSCA hlg(2700050C12Rik、C530008O16Rik、RIKEN cDNA2700050C12、RIKEN cDNA 2700050C12 gene); (9) ETBR (endothelin type B receptor); (10) MSG783 (RNF24, hypothetical protein FLJ20315); (11) STEAP2 [HGNC_8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostate cancer associated gene 1, prostate cancer associated protein 1, prostate six-segment transmembrane epithelial antigen 2, prostate six-segment transmembrane protein]; (12) TrpM4 [BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cation channel, subfamily M, member 4]; (13) CRIPTO [CR, CR1, CRGF, CRIPTO, TDGF1, teratocarcinoma-derived growth factor]; (14) CD21 (CR2 (complement receptor 2) or C3DR (C3d / Epstein Barr virus receptor) or Hs 73792); (15) CD79b (CD79B, CD79P, IGb (immunoglobulin-related β), B29); (16) FcRH2 (IFGP4, IRTA4, SPAP1A (SH-12 domain containing phosphatase anchor protein 1a), SPAP1B, SPAP1C); (17) HER2; (18) NCA; (19) MDP; (20) IL20Rα; (21) Brevican (B revican); (22) EphB2R; (23) ASLG659; (24) PSCA; (25) GEDA; (26) BAFF-R (B cell activating factor receptor, BLyS receptor 3, BR3); (27) CD22 (B cell receptor CD22-B isoform); (28) CD79a (CD79A, CD79α, immunoglobulin-related α); (29) CXCR5 (Burkitt's lymphoma receptor 1);(30) HLA-DOB (beta subunit of MHC class II molecule (Ia antigen)); (31) P2X5 (purinergic receptor P2X ligand-gated ion channel 5); (32) CD72 (B cell differentiation antigen CD72, Lyb-2); (33) LY64 [lymphocyte antigen 64 (RP105), type I membrane protein of the leucine-rich repeat (LRR) family]; (34) FcRH1 (Fc receptor-like protein 1); (35) IRTA2 (immunoglobulin superfamily receptor translocation-associated 2); (36) TENB2 (putative transmembrane proteoglycan) ; (37) Other options as immune effector cell-associated antigens include HGF, EGFR, EGFRvIII, Her2, Her3, IGF-1R, VEGF, VEGFR-1, VEGFR-2, VEGFR-3, Ang2, Dll4, NRP1, FGFR, FGFR2, FGFR3, c-Kit, MUC1, MUC16, CD20, CD22, CD27, CD30, CD33, CD40, CD52, CD70, CD79, DDL3, and Folate R1, Nectin 4. Trop2, gpNMB, Axl, BCMA, PD-1, PD-L1, PD-L2, CTLA4, BTLA, 4-1BB, ICOS, GITR, OX40, VISTA, TIM-3, LAG-3, KIR, B7.1, B7.2, B7-H2, B7-H3, B7-H4, B7-H6, B 7-H7, EphA2, EphA4, EphB2, E-selectin, EpCam, CEA, PSMA, PSA, c-MET, etc.; and (38) TCR / CD3, CD16 (FcγRIIIa) CD44, CD56, CD69, CD64 (FcγRI), CD89, CD11b / CD18 (CR3). ;

[0185] In one embodiment of the present disclosure, the antibody may include any antibody without limitation, as long as it can be used to prevent and treat proliferative diseases, particularly to treat cancer, and may include an antibody selected from, for example, alemtuzumab, apolizumab, aselizumab, atlizumab, bapineuzumab, bevacizumab, bivatuzumab mertansine, cantuzumab mertansine, cedelizumab, certolizumab pegol), cetuximab, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, ertumaxomab, felvizumab, fontolizumab, gemtuzumab, gemtuzumab ozogamicin, ibritumomab tiuxetan, inotuzumabozogamicin), ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab, nolovizumab, numavizumab, ocrelizumab, omalizumab, palivizumab, panitumumab, pascolizumab mab), pefusituzumab, pectuzumab, pertuzumab, pexelizumab, ralivizumab, ranibizumab, reslivizumab, reslizumab, resyvizumab, rituximab, rovelizumab, ruplizumab, sibrotuzumab, siplizumab, sontuzumab, tacatuzumab The invention may include members of the group consisting of tetraxetan, tadocizumab, talizumab, tefibazumab, tocilizumab, toralizumab, tositumomab, trastuzumab, tucotuzumab celmoleukin, tucusituzumab, umavizumab, urtoxazumab and visilizumab, but may not be limited thereto.

[0186] In one embodiment of the present disclosure, the joint used in the art and can be used for antibody-drug conjugates can be used without restriction. In this article, the joint is a chemical connector that attaches antibodies and drugs, which remains stable when circulating or distributed in the body, but is selectively cut to release the bound drug only when it penetrates into the tumor and enters the cell. Generally, the joint is composed of an attachment, a spacer and a releaser, and a new joint can be developed by modifying and / or improving at least one component of the attachment, spacer and releaser of a commercially available joint. In one embodiment of the present disclosure, not only joints commonly used in the art can be used, but also newly developed joints can be used, not limited to the joints.

[0187] In one embodiment of the present disclosure, the linker can be conjugated to the drug by chemical conjugation or enzymatic conjugation, but may not be limited thereto. Specifically, chemical conjugation may include lysine amide coupling, cysteine ​​coupling, or introduction of non-natural amino acids by genetic engineering, but may not be limited thereto. In addition, specifically, enzymatic conjugation may include transpeptidation using sortase, transpeptidation using microbial transglutaminase, or ortho-glycan engineering, but may not be limited thereto.

[0188] In one embodiment of the present disclosure, the linker may include at least one cleavable linker, which may be further cleaved; or at least one non-cleavable linker, but may not be limited thereto. In one embodiment of the present disclosure, the linker may include a cleavable linker, such as a disulfide linker (which is a reducible linker), an enzymatically cleavable linker, a hydrazone linker (which is a chemically unstable linker), a protease-unstable linker, or a glycosidase-sensitive linker; or a non-cleavable linker, such as a non-cleavable bifunctional linker or a non-cleavable spacer linker, but may not be limited thereto.

[0189] In one embodiment of the present disclosure, the linker may also include at least one cleavable linker, which can be further cleaved; or at least one non-cleavable linker, which is preferably selected from the following group: a hydrazine linker, a thiourea linker, a self-immolative linker, a succinimidyl trans-4-(maleimidomethyl)cyclohexane-1-carboxylate (SMCC) linker, a disulfide linker, a selenoether linker, an amide linker, a thioether linker and / or a maleimide linker.

[0190] In one embodiment of the present disclosure, it will be appreciated by those of ordinary skill in the art that additional linkers may be suitable. These linkers may not be cleaved or may be cleaved by pH changes, redox potential, or specific intracellular / extracellular enzymes. Cleavable oligopeptide linkers include linkers cleavable by proteases or matrix metalloproteinases. It should be understood that the linker may include the above combinations. For example, the linker may be a valine-citrulline PAB linker.

[0191] In one embodiment of the present disclosure, the linker may include N-succinimidyl-4-(2-pyridyldithio)pentanoate (SPP), N-succinimidyl-4-(2-pyridyldithio)butyrate (SPDB), a disulfide linker such as sulfo-SPDB, MDS, DMDS, DSDM or NDMDS; an enzymatically cleavable linker such as Phe-Lys-PABC, Val-Cit-PABC, Val-Ala-PABC, MHVCBC (valine-citrulline) or MHFKBC (phenylalanine-lysine); a hydrazone linker such as MHH; or a glucosidase-sensitive linker such as GBC (glucuronic acid), GBCDN (glucuronic acid), a β-glucuronide linker as a cleavable linker; or may include Mal-PEG-NHS, N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate as a non-cleavable linker (SMCC), Mal-alkane linker, bismaleimide polyethylene glycol (BMPEO), N-(β-maleimidopropyloxy) succinimide ester (BMPS), ε-maleimidocaproic acid N-hydroxysuccinimide ester (EMCS), γ-maleimidobutyric acid N-succinimide ester (GMBS), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), 4-(4-N-maleimidophenyl) )-butyric acid hydrazide (MPBH), N-succinimidyl 3-(bromoacetamido) propionate (SBAP), N-succinimidyl iodoacetate (SIA), N-succinimidyl-4-(iodoacetyl)-aminobenzoate (SIAB), N-succinimidyl 4-(p-maleimidophenyl) butyrate (SMPB) or succinimidyl-6-(maleimidopropionamido) hexanoate (SMPH), but may not be limited thereto.

[0192] In one embodiment of the present disclosure, the linker may include a member selected from the following, but may not be limited thereto:

[0193] BMPEO, BMPS, EMCS, GMBS, HBVS, long-chain N-succinimidyl 4-(maleimidomethyl) cyclohexane-1-carboxylate (long-chain SMCC), MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, N-(e-maleimidocaproyloxy)sulfosuccinimidyl ester (sulfo-EMCS), N-(y-maleimidobutyryloxy)sulfosuccinimidyl ester (sulfo-GMBS), N-(κ-maleimidoundecanoyloxy)sulfosuccinimidyl ester (sulfo-KMUS), m-maleimidobenzoyl-N-hydroxysulfosuccinimidyl ester (sulfo-MBS), sulfosuccinimidyl (4-iodoacetyl)aminobenzoate (sulfo bismaleimidoethane (BM(PEO)3), bismaleimidobutane (BMB), bismaleimido-2,3-dihydroxybutane (BMDB), bismaleimidohexane (BMH), bismaleimidoethane (BMOE), 1,8-bismaleimidodiethylene glycol [BM(PEO)2], and 1,11-bismaleimidotriethylene glycol [BM(PEO)3]; and

[0194]

[0195]

[0196]

[0197] In the above linkers, each dotted line may represent a covalent bond to an antibody or a benzoselenophene compound, and n may be from about 1 to about 1,000.

[0198] In one embodiment of the present disclosure, n may be from about 1 to about 1,000, from about 1 to about 900, from about 1 to about 800, from about 1 to about 700, from about 1 to about 600, from about 1 to about 500, from about 1 to about 400, from about 1 to about 300, from about 1 to about 200, from about 1 to about 100, from about 1 to about 50, from about 1 to about 40, from about 1 to about 30, from about 1 to about 20, from about 1 to about 10, from about 1 to about 5, or from about 1 to about 3, but may not be limited thereto. In one embodiment of the present disclosure, n may be from about 1 to about 5, or from about 1 to about 3.

[0199] In one embodiment of the present disclosure, by adjusting the n polyethylene glycols (PEGs) of the linker to form a PEG with a molecular weight of, for example, about 1,000 or about 2,000 or to form a 4-arm or 8-arm branched PEG, a DNA alkylation derivative with increased water solubility containing a benzoselenol-based compound can be synthesized and used as an anticancer drug or a precursor thereof, but may not be limited thereto.

[0200] In one embodiment of the present disclosure, the antibody-drug conjugate of the present disclosure may be a substance having a highly effective anti-cancer effect on cancer cells, wherein the IC against cancer cells 50 In the nM or pM range, but may not be limited thereto.

[0201] In one embodiment of the present disclosure, the linker and the benzoselenophene-based compound may be connected via a peptide bond, but may not be limited thereto.

[0202] In one embodiment of the present disclosure, if the functional group is substituted, the substituent may include one or more members selected from the group consisting of acyl, amino (including amino, monoalkylamino and dialkylamino, monoarylamino and diarylamino, and alkylarylamino), acylamino (including carbamoyl and ureido), alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, alkoxycarbonyl, carboxyl, carboxylate, aminocarbonyl, monoalkylaminocarbonyl and dialkylaminocarbonyl, cyano, azido, halogen, alkylamino ... The invention also includes a halogen group, a hydroxyl group, a nitro group, a trifluoromethyl group, a thiol group, an alkylthiol group, an arylthiol group, an alkylthiocarbonyl group, a thiocarboxylate group, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, a lower alkoxy group, an aryloxy group, an aryloxycarbonyloxy group, a benzyloxy group, a benzyl group, a sulfinyl group, an alkylsulfinyl group, a sulfonyl group, a sulfate group, a sulfonate group, a sulfonamide group, a phosphate group, a phosphonate group, a phosphinate group, an oxo group, a guanidinyl group, an imino group, and a formyl group, but may not be limited thereto.

[0203] In one embodiment of the present disclosure, R 1 may include a C 3-10 Heterocycloalkyl or C 3-10 heteroaryl, and R 4 and R 5 Each may be independently hydrogen, methyl or ethyl, but is not limited thereto.

[0204] In one embodiment of the present disclosure, X may be F, Cl, Br or I, but may not be limited thereto. In addition, in one embodiment of the present disclosure, X may be Cl.

[0205] In one embodiment of the present disclosure, the benzoselenophene-based compounds of the present disclosure are in the -CHR 2 CHR 1 R3 Contains two sp 3 The carbon atoms (which are connected to the benzoselenophene main body through an amide bond) serve as the main framework, thus increasing the flexibility of the molecule itself. In addition, ideally, R 1 Various derivatives may include pentagonal or hexagonal rings containing N, O or S. In addition, R 1 Bicyclic rings with or without heteroatoms may be included, which may promote DNA minor groove binding in anticancer mechanisms.

[0206] In one embodiment of the present disclosure, R 1 Can include pyrrolidinyl (-NC4H8), piperidinyl (-NC5H 10 ), piperazinyl (-N2C4H9), 4-methylpiperazin-1-yl (-N2C5H 11 ), morpholino (-NOC4H8), Y may include -CH2- or -C2H4-, Z may include -CHR-, -NR, -O- or -S-, and R may include hydrogen or C 1-3 Alkyl, but may not be limited thereto.

[0207] In one embodiment of the present disclosure, R 1 It can be pyrrolidinyl (-NC4H8), piperidinyl (-NC5H 10 ), piperazinyl (-N2C4H9), 4-methylpiperazin-1-yl (-N2C5H 11 ) or morpholino (-NOC4H8).

[0208] In one embodiment of the present disclosure, R 2 and R 3 Both can be hydrogen.

[0209] In one embodiment of the present disclosure, R 5 and R 6 Each may independently be hydrogen, methyl, ethyl or propyl.

[0210] In one embodiment of the present disclosure, the benzoselenophene-based compound may include the following:

[0211] [Compound 3]

[0212]

[0213] [Compound 4]

[0214]

[0215] In one embodiment of the present disclosure, the bond between the benzoselenophene compound of the present invention and the linker can be prepared by, for example, the following method, but is not limited thereto:

[0216]

[0217] In one embodiment of the present disclosure, the drug-antibody ratio (DAR) of the antibody-drug conjugate may be about 1 to about 8, but may not be limited thereto. In one embodiment of the present disclosure, the DAR of the antibody-drug conjugate may be about 1 to about 8, about 1 to about 6, about 1 to about 5, about 2 to about 8, about 2 to about 6, about 2 to about 5, about 3 to about 8, about 3 to about 6, or about 3 to about 5, but may not be limited thereto. In addition, in one embodiment of the present disclosure, the DAR of the antibody-drug conjugate may be about 2 to about 5.

[0218] According to a fifth aspect of the present disclosure, an anti-cancer composition is provided, comprising the antibody-drug conjugate according to the fourth aspect or a pharmaceutically acceptable salt thereof.

[0219] The detailed descriptions about the fifth aspect of the present disclosure that overlap with those about the first to fourth aspects of the present disclosure are omitted below, but the descriptions of the first to fourth aspects of the present disclosure can be applied identically to the fifth aspect of the present disclosure, even though they are omitted below.

[0220] In one embodiment of the present disclosure, the anticancer composition can be selected from solid tumors, hematological malignancies, colorectal cancer, uterine cancer, uterine fibroids, meningioma, lung cancer, small cell lung cancer, non-small cell lung cancer, gastrointestinal malignancies, colorectal cancer, intestinal cancer, breast cancer, ovarian cancer, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, brain cancer, brain metastases, sarcoma, osteogenic sarcoma, Kaposi's sarcoma and melanoma (but may not be limited thereto) at least one disease has anticancer activity. The pharmaceutical composition according to one embodiment of the present disclosure can be applied to various diseases as a target for prevention or treatment, not limited to the type of cancer.

[0221] Hereinafter, the present disclosure will be explained in more detail with reference to examples. However, the following examples are illustrative only for better understanding of the present disclosure, and do not limit the present disclosure.

[0222] [Example]

[0223] 1. Synthesis of intermediates

[0224] (1) Preparation of 5-(3-morpholinopropionamido)benzo[b]selenophene-2-carboxylic acid (Compound 7)

[0225]

[0226] 3-Morpholinopropionic acid (3 eq.), EDC (3 eq.) and DMAP (2 eq.) were dissolved in DMF and stirred for 15 min, then mixed with (ethyl)(5-amino-benzo[b]selenophene-2-carboxylate) (Compound 5, 1 eq.) for 24 h. After the reaction was complete, dichloromethane (MC) / water was used to separate the MC layer using a separatory funnel, then dried over MgSO4 and filtered. The solvent was removed from the filtrate by rotary evaporator, followed by column chromatography. Yield: 78%.

[0227] 1 H NMR (500.1MHz, CDCl3) δ1.38(t,3H,J=7,2),2.54-2.76(m,8H),3.82(t,4H,J=4.4),4.36(q,2H,J=7.2 ),7.36(dd,1H,J=8.6,2.1),7.77(d,1H,J=8.6),8.21(s,1H),8.26(d,1H,J=2.2),10.87(bs,1H,NH); 13 C NMR (125.7 MHz, CDCl3) δ 14.4, 32.3, 52.9, 54.2, 61.7, 67.1, 117.6, 119.7, 126.1, 134.2, 136.3, 137.7, 138.8, 141.9, 163.9, 170.5; HRMS (ESI); for C 18 H 22 m / z calculated for N2O4Se[M+]: 410.07; found: 411.0824[M+H]+

[0228] The (ethyl)(5-(3-(morpholino)propionamido)benzo[b]selenophene-2-carboxylate) (1 equivalent) obtained in the above process was dissolved in methanol and then reacted with 2 mL of 3N NaOH for 24 h. After the reaction was completed, 20% HCl was added thereto to adjust the pH to acidic. The solvent was then removed by rotary evaporator, followed by column chromatography. Yield: 90%.

[0229] 1 H NMR (500.1MHz, MeOD-d4) δ2.74-3.11(m,8H),3.81(s,4H),7.48(d,1H,J=8.4),7.87(d,1H,J=8.9),8.08(s,1H),8.21(s,1H);

[0230] 13C NMR (125.7 MHz, DMSO-d6) δ 30.2, 51.1, 51.8, 63.2, 117.2, 119.7, 126.4, 133.9, 136.6, 137.8, 138.8, 141.6, 164.7, 167.9; HRMS (ESI); for C 16 H 18 m / z calculated for N2O4Se[M+]: 382.04; found: 383.0512[M+H]+.

[0231] (3) Preparation of 5-(3-(4-methylpiperazin-1-yl)propionamido)benzo[b]selenophene-2-carboxylic acid (Compound 8)

[0232] 3-(4-Methylpiperazine-1-yl)propionic acid (3 eq.), EDC (3 eq.) and DMAP (2 eq.) were dissolved in DMF and stirred for 15 min, then reacted with (ethyl)(5-amino-benzo[b]selenophene-2-carboxylate) (Compound 5, 1 eq.) for 24 h. After the reaction was complete, dichloromethane (MC) / water was used to separate the MC layer with a separatory funnel, then dried with MgSO4 and filtered. The solvent was removed from the filtrate by a rotary evaporator, followed by column chromatography. Yield: 84%.

[0233] 1 H NMR (500.1MHz, CDCl3) δ1.14(t,2H,J=7,1),1.34(t,3H,J=7.2),2.31(s,3H),2.48-2.50(m,4H),2.68-2.70(m,4H),3.41 (q,2H,J=7.1),4.31(q,2H,J=7.1),7.34(d,1H,J=8.7),7.72(d,1H,J=8.6),8.16(s,1H),8.22(s,1H),11.02(bs,1H,NH);

[0234] 13 C NMR (125.7 MHz, CDCl3) δ 14.3, 15.3, 32.6, 46.0, 52.3, 53.6, 55.3, 61.6, 65.8, 117.5, 119.7, 126.0, 134.3, 136.5, 137.5, 138.5, 141.8, 163.8, 170.7; HRMS (ESI); for C 19 H 25 m / z calculated for N3O3Se[M+]: 423.11; found: 424.1139[M+H]+.

[0235] The (ethyl)(5-(3-(4-methylpiperazin-1-yl)propionamido)benzo[b]selenophene-2-carboxylate) (1 equivalent) obtained in the above process was dissolved in methanol and then reacted with 2 mL of 3N NaOH for 24 h. After the reaction was completed, 20% HCl was added thereto to adjust the pH to acidic. The solvent was then removed by rotary evaporator, followed by column chromatography. Yield: 62%.

[0236] 1 H NMR(500.1MHz,MeOD-d4)δ2.54-2.58(m,2H),2.66(s,3H),2.77-3.05(m,9H), 3.27(s,1H),7.38(d,1H,J=8.6),7.74(d,1H,J=8.6)7.90(s,1H),8.08(s,1H);

[0237] 13 C NMR (125.7 MHz, DMSO-d6) δ 34.9, 44.0, 51.5, 51.8, 54.2, 54.4, 54.7, 118.8, 120.2, 127.1, 131.3, 137.1, 140.1, 144.2, 149.1, 171.0, 172.5; HRMS (ESI); for C 17 H 21 m / z calculated for N3O3Se[M+]: 395.07; found: 396.0826[M+H]+.

[0238] 2. Preparation of the final product by reaction of the intermediate product with seco-MCBI

[0239] By using methods known in the art, seco-MCBI (Compound 1) for synthesis was synthesized. The method for synthesizing Compounds 3 and 4 by coupling benzoselenophene carboxylic acid to the obtained intermediate product by acid treatment was carried out by the following method:

[0240]

[0241] The reaction mixture was prepared by adding 4 mL of HCl saturated solution (in ethyl acetate) to a round-bottom flask containing seco-MCBI (compound 1, 30 mg, 0.09 mmol) at -78 ° C. The reaction mixture was stirred at -78 ° C for 30 min and then stirred at room temperature for 1 h. After salt formation was observed by thin layer chromatography (TLC), ethyl acetate was evaporated under a nitrogen stream and then completely dried under high vacuum for 1 h. The resulting residue was dissolved in anhydrous DMF (0.2 mL), and a mixture of carboxylic acid (1.1 equivalents) and EDC (52 mg, 0.27 mmol) (expressed as compound 7 or 8) in anhydrous DMF (0.5 mL) was added at 0 ° C, then stirred at 0 ° C for 3 h and stirred at room temperature for 5 h. After the reaction was completed, the resulting product was diluted with water and extracted with ethyl acetate (3 × 15 mL). The obtained organic layer was washed with brine and dried with MgSO4, filtered and concentrated to obtain a crude product. The crude product was purified by column chromatography to obtain the desired product.

[0242] 3. Analysis results of the final product

[0243] (1) (S)-N-(2-(1-(chloromethyl)-5-hydroxy-8-methoxy-2,3-dihydro-1H-benzo[e]indole-3-carbonyl)benzo[b]selenophene-5-yl)-3-morpholinopropanamide (Compound 3)

[0244]

[0245] 1 H NMR (500.1 MHz, acetone-d6) δ 10.28 (s, 1H), 9.31 (s, 1H), 8.48 (s, 1H), 8.21 (s, 1H), 8.14 (d, J = 9.2 Hz, 1H), 7.99 (m, 1H), 7.76 (brs, 1H), 7.54 (d, J = 8.6 Hz, 1H), 7.20 (s, 1H), 7. 03(d,J=9.3Hz,1H),4.76(t,J=9.5Hz,1H),4.65(d,J=11.0Hz,1H),4.18(m,1H),4.0 6(d,J=11.2Hz,1H),3.95(s,3H),3.82-3.78(m,1H),3.74(m,4H),2.64-2.62(m,6H),

[0246] 13 C NMR (500.1MHz, CDCl3 +Methanol-d4)δ171.3,164.2,159.7,155.4,143.5,142.7,142.3,138.3,136.6,132.0,130.6,126.2,126.0,120.2,118.9,118.4,116.2,106.5,101.8,98.8,66.7(2C),56.7,55.7,54.6,53.4(2C),46.2,45.3,43.0 for (C 30 H 30 HRMS calculated value of ClN3O5Se): 628.1088 [M+H]+, found value: 628.1087.

[0247] 4. Synthesis of mal-linker-payload (Compound 3-3)

[0248] (1) Synthesis of (S)-1-(chloromethyl)-8-methoxy-3-(5-(3-morpholinopropionamido)benzo[b]selenophene-2-carbonyl)-2,3-dihydro-1H-benzo[e]indol-5-yl(4-nitrophenyl) carbonate (Compound 3-1)

[0249] Compound 3 was dissolved in anhydrous THF and then filled with N2(g). Then, TEA (6 equivalents) and 4-nitrophenyl chloroformate (4 equivalents) were added thereto at 0°C and reacted at room temperature for 12h. After all THF was evaporated, phenol, pNPC and TEA were removed by ether precipitation. The resulting product was used as a crude product in the following reaction.

[0250] After the crude product was dissolved in DMF / THF (1:4), tert-butylmethyl(2-(prop-2-yn-1-ylamino)ethyl)carbamate (6 eq.) and TEA (2 eq.) were added thereto at 0°C and the reaction was monitored by HPLC. After the reaction was completed, column chromatography was performed with MC / MeOH. Yield: 95%.

[0251] 1H NMR (500.1 MHz, acetone) δ 10.123 (s, 1H), 8.446 (s, 1H), 8.126-8.096 (q, 2H), 7.891-7.873 (d, 1H), 7.445-7.428 (d, 1H), 7.204-7.176 (t, 1H), 7.086-7.041 (q, 1H), 4.702-4.4 (m, 3H), 4.323 (s, 1H), 4.211 -4.198(d,1H),4.030-3.860(m,5H),3.666-3.650(q,6H),3.546-3.534(d,1H),3.275(s,1H),3.2 ~2.8(m,6H),2.676-2.668(s,2H),2.492-2.437(t,6H),2.049-2.005(m,3H),1.464-1.399(t,9H); 13 C NMR (500.1MHz, acetone)δ170.94163.15160.05156.53155.98155.06154.78149.13148.89145.41143.78143.06138.08137.46132.41131.10126.50125.32122.68121.21119.97118.8117.82109.80109.74102.4080.4479.9279.8274.2667.4756.4655.9555.07 54.0147.41 47.09 46.54 46.13 45.63 42.92 38.16 37.65 37.33 35.28 34.92 34.17 28.7328.67.

[0252] (2) Synthesis of (2R,3R,4R,5S,6S)-3,4,5-triacetoxy-6-(4-((((2-(((((S)-1-(chloromethyl)-8-methoxy-3-(5-(3-morpholinopropionamido)benzo[b]selenophene-2-carbonyl)-2,3-dihydro-1H-benzo[e]indol-5-yl)oxy)carbonyl)(prop-2-yn-1-yl)amino)ethyl)(methyl)carbamoyl)oxy)methyl)phenoxy)tetrahydro-2H-pyran-2-carboxylic acid (Compound 3-2)

[0253] Compound 3-1 was dissolved in TFA (20% in the presence of dichloromethane as a solvent), and the temperature was raised from 0°C to room temperature. The reaction was monitored by HPLC, and then dried repeatedly with MC. The resulting product was then used as a crude product in the following reaction.

[0254] The crude product was dissolved in DMF / THF (1:1), and β-glucuronide linker carbonate (3 eq.) and TEA (2 eq.) were added thereto. The reaction was complete when the reactants were removed while being monitored by HPLC. Column chromatography was performed sequentially with ethyl acetate (EA): hexane, EA: methanol (MeOH), and MC: MeOH while being monitored by HPLC. Yield: 60.9%

[0255] 1 H NMR (500.1 MHz, acetone) δ10.9 (s, 1H), 8.4 (d, 1H), 8.1~8.0 (t, 2H), 7.9~7.7 (m, 2H), 7.45~7.32 (t, 1H), 7.3~7.2 (d, 1H), 7.2-7.1 (t, 1H), 7.1~6.85 (m, 2H), 5.5~5.3 (m, 1H), 5.2~4.9 (m, 4H), 4.7~4.5 ( m,2H),4.5~4.35(m,1H),4.3~4.25(s,1H),4.25~4.1(s,1H),4.0(d,1H),3.9~3.7(m,4H),3.7~3 .4(m,9H),3.0~2.8(m,4H),2.7~2.6(m,2H),2.55~2.3(m,6H),1.3~1.1(m,4H),0.85~0.7(m,3H).

[0256] The compound obtained in the above process (1 equivalent) was dissolved in methanol / water (6:1). LiOH (hydrate, 6 equivalents) was added thereto at 0°C and stirred for 1 h. The reaction was monitored by HPLC and then acidified to pH 3 by adding acetic acid to obtain a solid product. The solid product was filtered and impurities were removed with some acetone and MC. Yield: 99%.

[0257] 1H NMR (500.1MHz, DMSO) δ10.245(s,1H),8.474(s,1H),8.323(s,1H),8.072-7.970(q,2H),7.867-7.721(m,1H),7. 467(s,1H),7.324-7.229(q,3H),7.121(s,1H),6.960-6.861(t,2H),5.411(s,1H),5.208(s,1H),5.029-4.866( m,4H),5.411(s,1H),5.208(s,1H),5.029-4.866(t,4H),4.548-4.533(d,1H),4.400(s,2H),4.225-4.042(q,4H ), 4.0~3.5(m,17H),2.933(s,1H),2.871(s,1H),2.668-2.656(d,3H),2.441(s,3H),2.086(s,3H),1.140(s,1H).

[0258] (3) Synthesis of (2R,3R,4R,5S,6S)-3,4,5-triacetoxy-6-(4-((((2-(((((S)-1-(chloromethyl)-8-methoxy-3-(5-(3-morpholinopropionamido)benzo[b]selenophene-2-carbonyl)-2,3-dihydro-1H-benzo[e]indol-5-yl)oxy)carbonyl)((1-(15-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-13-oxo-3,6,9-trioxa-12-azapentadecanyl)-1H-1,2,3-triazol-4-yl)methyl)amino)ethyl)(methyl)carbamoyl)oxy)methyl)phenoxy)tetrahydro-2H-pyran-2-carboxylic acid (Compound 3-3)

[0259] Compound 3-2 (1 equivalent) and 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethylamine (1.5 equivalents) were dissolved in DMSO, and CuSO4 (1 equivalent) and THPTA (1 equivalent) were dissolved in a buffer solution and then placed in the DMSO solution of compound 3-2. After sodium ascorbate (10 equivalents) was added thereto for 20 minutes, the reaction was monitored by HPLC. After the reaction was completed, separation was performed by HPLC. Yield: 82%.

[0260] 1H NMR(500.1MHz,DMSO)δ10.396(s,1H),8.451(s,1H),8.073-8.056(d,1H),8.073-8.056(q,2H),7.728(m,3H),7. 511-7.493(d,1H),7.282-7.205(t,3H),7.103-7.085(d,1H),7.000-6.940(m,2H),5.754(s,0.5H),5.1~4.9(m,3 H),4.9~4.7(m,2H),4.6~4.5(s,4H),4.4~4.3(s,1H),4.2~3.9(m,7H),3.9~3.8(s,3H),3.75~3.6(s,2H),3.6~3. 4(m,8H),3.2~3.1(s,9H),3.0~2.8(m,6H),2.6~2.45(m,6H),2.14~2.05(s,4H),1.8~1.7(s,2H),1.3~1.2(s,1H).

[0261] After the compound obtained in the above process was dissolved in DMF, DIPEA (2 equivalents) and 2,5-dioxopyrrolidin-1-yl-3-(2,5-dioxo-2,5-dihydro-1H)-pyrrol-1-yl) propanoate (1.5 equivalents) were added thereto and stirred at room temperature for 2 h. Yield: 23%

[0262] 1 H NMR(500.1MHz,DMSO)δ10.383(s,1H),8.439(s,1H),8.35-8.3(d,1H),8.073-8.056(d,1H),7.978-7 .951(t,3H),7.85-7.6(m,1H),7.510-7.492(d,1H),7.272-7.199(d,3H),7.097-7.080(t,1H),6.99 5-6.940(q,3H),5.000~4.7(m,4H),4.6~4.5(m,4H),4.45~4.3(s,1H),4.15~3.6(m,10H),3.6~3.2(m ,9H),3.2~3.1(m,3H),3.0~2.8(m,8H),2.8~2.7(s,3H),2.7~2.3(m,9H),1.753(s,2H),1.234(s,1H).

[0263] 5. Synthesis of Trastuzumab-Payload (Compound 3, DS-24) Conjugate

[0264]

[0265] Trastuzumab (TmAb) was used as the antibody and was used after purification by gel permeation chromatography. The antibody used has two disulfide bonds connecting HC and LC and two disulfide bonds connecting HC and HC, thus having a total of four interchain disulfide bonds. The antibody was partially reduced with a mild reducing agent tris(2-carboxyethyl)phosphine hydrochloride (TCEP). When the DAR is about 2 to about 5, there is no problem with the antigen-antibody reaction, and the toxicity is high. Therefore, the equivalent of TCEP is adjusted to obtain a DAR average value of about 2 to about 5.

[0266] After TmAb (1 equivalent) was dissolved in PBS (pH = 7.25), it was reduced with TCEP (2.75 equivalents) in an incubator for 30 min, and then GPC was performed to obtain only the reduced antibody. After checking the presence or absence of the antibody with a UV spectrometer, 1 mM DTPA was added. Mal-linker-drug (10 equivalents) was dissolved in DMSO (DMSO 5%, PBS buffer 95%) at 5 mg / ml, and 2 equivalents were added each time. After hydrophobic interaction chromatography (HIC) was performed every 30 min at 37°C in an incubator, Mal-linker-drug was further added. After the reaction was completed, a pure sample was obtained by GPC and mixed with 30 mM histidine, 80 mM trehalose, 0.01% 20 and 50 mM PBS (pH 6) buffer solutions were prepared by centrifugation. Then, they were dried in a lyophilizer and stored.

[0267] 6. Analysis results of synthetic antibody-drug conjugates (ADCs)

[0268] (1) Size Exclusion Chromatography (SEC) Analysis of Trastuzumab-Glucuronide Compound 3ADC

[0269] SEC elutes the larger particles first. Therefore, if it elutes earlier than the antibody, it can be checked for aggregation. Figure 1 As shown, as a result of synthesizing ADC containing compound 3, aggregation was measured to be 1% or less, confirming that there was almost no aggregation.

[0270] (2) Hydrophobic interaction chromatography (HIC) analysis of trastuzumab-glucuronide-compound 3 ADC

[0271] like Figure 2 As shown, samples with a drug-antibody ratio (DAR) of 2, 4, 6, 8, etc. are combined with a sample with a DAR of 0 to show 1, which means that the linker-drug used has high polarity and good water solubility.

[0272] (3) Polymer-based reverse phase (PLRC) analysis of trastuzumab-glucuronide-Compound 3 ADC

[0273] In PLRP, each part of the reduced antibody is reduced (completely reduced) and displayed on the spectrum separately, so it is possible to check which part of the antibody is connected to the linker-drug. Figure 3 As shown, when ADC is reduced, it dissociates into light and heavy chains. Figure 3 Data obtained by quantitatively analyzing one not connected to the light chain (L0), one connected to the light chain (L1), one not connected to the heavy chain (H0), and one, two, and three connected to the heavy chain (H1, H2, and H3) are shown. Thus, DAR was confirmed to be 4.25.

[0274] 7. Anticancer activity analysis of compound 3 and ADC containing it

[0275] (1) In vitro cell line activity analysis of compound 3

[0276] The activity of compound 3 was checked by requesting samples from the NCI NTP program. Figure 4 As shown, compound 3 exhibited very strong activity in a variety of cell lines, including GI 50 The activity index (for growth inhibition of 50%, NCI NTP program) was pM or lower, showing particularly strong activity in non-small lung cancer, CNS cancer, melanoma and renal cancer (kidney cancer).

[0277] (2) In vivo cell line activity analysis of compound 3

[0278] The results of the in vivo cell line activity analysis of compound 3 (DS-24) confirmed that it has in vivo activity even at very low concentrations, such as Figure 5 shown.

[0279] (3) Correlation analysis between compound 3 and corresponding cancer types in NCI cell lines [sensitivity differences between cancer types (TGI)]

[0280] based on Figure 6 Results shown analyze whether there is any statistical significance in the responsiveness depending on the cancer type in the cell lines in which the anticancer effect has been demonstrated through the NCI NTP program. Figure 6 As shown, it was confirmed that compared with leukemia, non-small cell lung cancer, CNS cancer and melanoma had a tumor growth inhibitory effect. In addition, the significant difference in TGI between leukemia and melanoma was confirmed by Wilcoxon rank sum test, and the p value was 0.0074 (<0.05). Based on this, it was determined that when compound 3 was applied to antibody-drug conjugates, it could show significant efficacy in brain tumors, brain metastases (NSCLC), lung cancer and melanoma.

[0281] (4) Activity analysis of trastuzumab-glucuronide-compound 3 ADC [ADC (DS-24)]

[0282] 1) Analysis of the activity of ADC (DS-24) that depends on the expression of Her2

[0283] The following synthesized ADC was analyzed, with a DAR of 4.25 and exhibited similar activity for both formulations (ADC F1 and ADC F2). It can be seen that the activity was excellent in SK-Br-3 and JIMT-1 cell lines where Her2 (trastuzumab antigen) is highly expressed, while the activity was low in MCF-7 where Her2 is lowly expressed and used as a control group. The high activity at 168h of treatment is believed to be because the linker used is unstable in the MCF-7 cell line.

[0284]

[0285] [Table 1]

[0286]

[0287] 2) Cell viability analysis of MCF-7 cells and NCI-N87 cells treated with ADC (DS-24)

[0288] MCF-7 cells and NCI-N87 cells were treated with 7 different concentrations of ADC (DS-24) ranging from 0.02 nM to 100 nM for 3 days. Figure 7a Nonlinear regression analysis of the dose-response curves is shown. Figure 7b As a result, the IC 50 Value data.

[0289] NCI-N87 cells expressing Her2 are sensitive to trastuzumab-Compound 3 ADC, while Her2-negative MCF-7 cells are resistant to it. Figure 7a and Figure 7b As shown, MCF-7 cells and NCI-N87 cells were treated with trastuzumab-glucuronide-compound 3 ADC, and then the intracellular ATP level was measured to analyze the viability. As a result, NCI-N87 expressing the antigen of trastuzumab showed high sensitivity, while MCF7 not expressing the antigen showed low sensitivity.

[0290] 3) Examining the effect of ADC (DS-24) on the inhibition of BT474 tumor spheroids

[0291] like Figure 8aAs shown, after forming three-dimensional tumor spheroids in the Her2-expressing BT474 cell line (an antigen that highly expresses trastuzumab), they were treated with 7 different concentrations of trastuzumab and trastuzumab-glucuronide-Compound 3 ADC ranging from 0.02nM to 100nM and observed after 2 weeks. Figure 8b and Figure 8c As shown in Figure 2, the high anticancer activity of ADC (DS-24) was confirmed by nonlinear regression analysis of the dose-response curve, and the IC 50 The IC value of ADC (DS-24) was 18.19 nM. 50 Assayed at 0.23 nM.

[0292] 4) Effect of ADC (DS-24) on body weight changes in the NCI-N87 xenograft animal model

[0293] After the NCI-N87 cell line expressing the antigen of trastuzumab was xenografted into nude mice, each of trastuzumab and trastuzumab-glucuronide-compound 2 [ADC (DS-24)] was intravenously administered, and then the anticancer activity was observed. Here, trastuzumab was administered at 5 mg / kg twice a week, and ADC (DS-24) was administered once at a dose of 1 mg / kg and 5 mg / kg.

[0294] like Figure 9a As shown in the figure, the group administered with trastuzumab and the group administered with 1 mg / kg ADC (DS-24) showed a certain degree of inhibition of tumor formation, which was not significant. The group administered with 5 mg / kg ADC (DS-24) showed no increase in tumor size before day 49, which was significant compared with the above two groups. Figure 9b As shown, there was no significant change in the body weight of the mice during the administration period. Therefore, in the group administered with ADC (DS-24), no side effects such as severe body weight changes were found, confirming that no toxicity occurred.

[0295] 5) Toxicity analysis of ADC (DS-24) by complete blood count (CBC) assay in NCI-N87 xenograft animal model

[0296] In the efficacy evaluation in the NCI-N87 xenograft model, blood was collected from mice at the end of the evaluation for all subjects and analyzed by complete blood count using a hemacytometer to determine how the antibody-drug conjugate affected the entire circulatory system of the mice.

[0297] like Fig.10aAs shown in Figure 2, in the control group and the administration group, the levels of inflammatory cells such as white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM) and monocytes (MONO) were within the normal range. Fig.10b As shown, anemia-related values ​​(eg, red blood cells, hemoglobin, and hematocrit) did not reveal any significant findings, and mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and platelet count (PLT) were also examined.

[0298] 6) Evaluate the effect of DS-24 free toxin in cell lines and cells derived from brain tumor patients by high-throughput screening

[0299] Fig.11a , Fig.11b and Fig.11c Data demonstrating the cell viability inhibition effects of seven payloads other than compound 3 (DS-24) on glioblastoma cell line U87MG, multiple myeloma cell line KMS11, and bladder cancer cell line RT112, respectively, are shown. In addition, Fig.12a , Figure 12b , Fig.12c , Fig.12d , Fig.12e and Fig.12f Shown are data demonstrating the cell viability inhibitory effects of seven payloads, except Compound 3 (DS-24), respectively, on six cell types derived from patients with glioblastoma.

[0300] After treatment with drugs diluted to 14 different concentrations based on 20 μM as the highest concentration, the concentration graph of two replicates was used to verify whether the effect was proportional to the drug concentration. Cell viability was analyzed 7 days after drug treatment to calculate the IC for 50% inhibition of cell viability. 50 .

[0301] IC analyzed 50 The values ​​are shown in Table 2 below. DM1, DM4, MMAE, and MMAF showed significantly lower cell viability inhibition in glioblastoma patient-derived cells compared to KMS11 and RT112. SN-38 and deruxtecan-linkers showed similar efficacy in all cells but had lower cell viability inhibition compared to the other payloads. DS-24 showed the highest cell viability inhibition among the comparative substances.

[0302] In particular, DS-24 exhibited an IC 50 The value is the IC of the other effective loads being compared 50Therefore, it is believed that the DS-24 drug according to the present invention effectively inhibits the cell viability of brain tumors and glioblastomas compared with other drugs.

[0303] [Table 2]

[0304]

[0305] 8. Analysis of the anticancer activity of compound 3 compared with compound 2

[0306] Although the present inventors previously prepared the following compound 2 and analyzed its anticancer activity, the following compound 3 according to the present disclosure was confirmed to have significantly superior anticancer activity compared to compound 2. Specifically, a cell growth inhibition assay was performed:

[0307] [Compound 2] (DS-26)

[0308]

[0309] [Compound 3](DS-24)

[0310]

[0311] Her2-positive human gastric cancer cells NCI-N87 and human ovarian cancer cells SK-OV3 purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA) were seeded into 384-well plates at 500 cells / well. Two hours after plating, the cells were treated with toxins in 5-fold and 14-point serial dilution series, repeated four times. After incubation for 3 days at 37°C in a 5% CO2 humidified incubator, cell viability was checked using a firefly luciferase-based adenosine triphosphate monitoring system (ATPliteTM 1step, PerkinElmer, MA, USA). IC 50 The values ​​were calculated as the average of four replicates (GraphPad Prism 5.0, CA and USA). The specific experimental values ​​are shown in Table 3 below. Fig.13a and Fig.13b are graphs showing cell viability of NCI-N87 depending on the concentrations of DS-24 and DS-26, respectively, Fig.14a and Fig.14b are graphs showing cell viability of SK-OV3 depending on the concentrations of DS-24 and DS-26, respectively.

[0312] [Table 3]

[0313]

[0314]

[0315] (*AUC: Area Under the Curve)

[0316] The above description of the present disclosure is provided for the purpose of illustration, and it should be understood by those skilled in the art that various changes and modifications may be made without changing the technical concept and essential features of the present disclosure. Therefore, it is apparent that the above embodiments are illustrative in all respects and do not limit the present disclosure. For example, each component described as a single type may be implemented in a distributed manner. Similarly, components described as distributed may be implemented in a combined manner.

[0317] The scope of the present disclosure is defined by the appended claims rather than the detailed description of the embodiments. It should be understood that all modifications and embodiments contemplated by the meaning and scope of the claims and their equivalents are included within the scope of the present invention.

Claims

1. A benzoselenophene compound represented by the following chemical formula 1: [Chemical formula 1] In the above chemical formula 1, R 1 is a substituted or unsubstituted C 3-10 heterocycloalkyl, or a substituted or unsubstituted C 3-10 Heteroaryl, R 2 and R 3 are each independently hydrogen, fluorine, chlorine, bromine, iodine or substituted or unsubstituted C 1-5 alkyl, R 4 and R 5 are each independently hydrogen, or substituted or unsubstituted C 1-5 alkyl, The C 3-10 The heterocycloalkyl group and the C 3-10 The heteroaryl group may or may not contain at least one heteroatom selected from O and S, and X is a halogen, If R 1 , R 2 , R 3 , R 4 and R 5 If at least one of is substituted, then R 1 , R 2 , R 3 , R 4 and R 5 The substituent of at least one of the above is at least one selected from the following: amino, C 1-12 Alkylcarbonyloxy, carboxyl, carboxylate, aminocarbonyl, mono-C 1-12 Alkylaminocarbonyl, di-C 1-12 Alkylaminocarbonyl, cyano, azido, halogen, hydroxyl, nitro, trifluoromethyl, thiol, C 1-12 Alkylthiol, C 1-12 Alkylthiocarbonyl, thiocarboxylate, C 1-12 Alkyl, benzyloxy, benzyl, sulfinyl, C 1-12 Alkylsulfinyl, sulfonyl, sulfate, sulfonate, sulfonamide, phosphate, phosphonate, phosphinate, oxo, guanidino, imino and formyl.

2. The benzoselenophene compound according to claim 1, Where R 4 and R 5 Each is independently hydrogen, methyl or ethyl.

3. The benzoselenophene compound according to claim 1, Where R 1 is pyrrolidinyl, piperidinyl, piperazinyl, 4-methylpiperazin-1-yl, morpholino, Y is -CH 2 -or-C 2 H 4 -, Z is -CHR-, -NR, -O- or -S-, and R is hydrogen or C 1-3 alkyl.

4. The benzoselenophene compound according to claim 1, The benzoselenophene compound is compound 3 or compound 4: [Compound 3] or [Compound 4] 5. A pharmaceutical composition comprising a benzoselenophene compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof, The pharmaceutical composition is used to prevent or treat proliferative diseases: [Chemical formula 1] In the above chemical formula 1, R 1 is a substituted or unsubstituted C 3-10 heterocycloalkyl, or a substituted or unsubstituted C 3-10 Heteroaryl, R 2 and R 3 are each independently hydrogen, fluorine, chlorine, bromine, iodine or substituted or unsubstituted C 1-5 alkyl, R 4 and R 5 are each independently hydrogen, or substituted or unsubstituted C 1-5 alkyl, The C 3-10 The heterocycloalkyl group and the C 3-10 The heteroaryl group may or may not contain at least one heteroatom selected from O and S, and X is a halogen, If R 1 , R 2 , R 3 , R 4 and R 5 If at least one of is substituted, then R 1 , R 2 , R 3 , R 4 and R 5 The substituent of at least one of the above is at least one selected from the following: amino, C 1-12 Alkylcarbonyloxy, carboxyl, carboxylate, aminocarbonyl, mono-C 1-12 Alkylaminocarbonyl, di-C 1-12 Alkylaminocarbonyl, cyano, azido, halogen, hydroxyl, nitro, trifluoromethyl, thiol, C 1-12 Alkylthiol, C 1-12 Alkylthiocarbonyl, thiocarboxylate, C 1-12 Alkyl, benzyloxy, benzyl, sulfinyl, C 1-12 Alkylsulfinyl, sulfonyl, sulfate, sulfonate, sulfonamide, phosphate, phosphonate, phosphinate, oxo, guanidino, imino and formyl.

6. The pharmaceutical composition according to claim 5, The benzoselenophene compound or a pharmaceutically acceptable salt thereof is a prodrug.

7. The pharmaceutical composition according to claim 5, The proliferative disease is at least one selected from the group consisting of tumors, psoriasis, bone diseases, fibroblast disorders and atherosclerosis.

8. The pharmaceutical composition according to claim 7, Wherein the tumor is cancer, and the cancer is a solid tumor or a hematological malignancy.

9. The pharmaceutical composition according to claim 5, Where R 4 and R 5 Each is independently hydrogen, methyl or ethyl.

10. The pharmaceutical composition according to claim 5, Where R 1 is pyrrolidinyl, piperidinyl, piperazinyl, 4-methylpiperazin-1-yl, morpholino, Y is -CH 2 -or-C 2 H 4 -, Z is -CHR-, -NR, -O- or -S-, and R is hydrogen or C 1-3 alkyl.

11. The pharmaceutical composition according to claim 5, The benzoselenophene compound is compound 3 or compound 4: [Compound 3] or [Compound 4] 12. The pharmaceutical composition according to claim 7, Wherein the tumor is a cancer, and the cancer is at least one selected from the group consisting of leukemia, uterine cancer, uterine fibroids, meningioma, lung cancer, gastrointestinal malignancies, breast cancer, ovarian cancer, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, brain cancer, sarcoma and melanoma.

13. The pharmaceutical composition according to claim 7, The tumor is a cancer, and the cancer is at least one selected from the group consisting of brain metastases, intestinal cancer, small cell lung cancer, non-small cell lung cancer, osteogenic sarcoma and Kaposi's sarcoma.

14. An antibody-drug conjugate or a pharmaceutically acceptable salt thereof, include: Antibody; Connectors; and A benzoselenophene compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof: [Chemical formula 1] In the above chemical formula 1, R 1 is a substituted or unsubstituted C 3-10 heterocycloalkyl, or a substituted or unsubstituted C 3-10 Heteroaryl, R 2 and R 3 are each independently hydrogen, fluorine, chlorine, bromine, iodine or substituted or unsubstituted C 1-5 alkyl, R 4 and R 5 are each independently hydrogen, or substituted or unsubstituted C 1-5 alkyl, The C 3-10 The heterocycloalkyl group and the C 3-10 The heteroaryl group may or may not contain at least one heteroatom selected from O and S, and X is a halogen, If R 1 , R 2 , R 3 , R 4 and R 5 If at least one of is substituted, then R 1 , R 2 , R 3 , R 4 and R 5 The substituent of at least one of the above is at least one selected from the following: amino, C 1-12 Alkylcarbonyloxy, carboxyl, carboxylate, aminocarbonyl, mono-C 1-12 Alkylaminocarbonyl, di-C 1-12 Alkylaminocarbonyl, cyano, azido, halogen, hydroxyl, nitro, trifluoromethyl, thiol, C 1-12 Alkylthiol, C 1-12 Alkylthiocarbonyl, thiocarboxylate, C 1-12 Alkyl, benzyloxy, benzyl, sulfinyl, C 1-12 Alkylsulfinyl, sulfonyl, sulfate, sulfonate, sulfonamide, phosphate, phosphonate, phosphinate, oxo, guanidino, imino and formyl.

15. The antibody-drug conjugate according to claim 14 or a pharmaceutically acceptable salt thereof, Wherein the antibody-drug conjugate or a pharmaceutically acceptable salt thereof is a prodrug.

16. The antibody-drug conjugate according to claim 14 or a pharmaceutically acceptable salt thereof, The antibodies include antibodies, antibody variants or antigen-binding fragments thereof that are immunospecific for proliferative diseases.

17. The antibody-drug conjugate according to claim 16 or a pharmaceutically acceptable salt thereof, The proliferative disease is at least one selected from the group consisting of tumors, psoriasis, bone diseases, fibroblast disorders and atherosclerosis.

18. The antibody-drug conjugate according to claim 17 or a pharmaceutically acceptable salt thereof, Wherein the tumor is cancer, and the cancer is a solid tumor or a hematological malignancy.

19. The antibody-drug conjugate according to claim 14 or a pharmaceutically acceptable salt thereof, wherein the antibody is selected from the group consisting of alemtuzumab, apolizumab, asekizumab, atezolizumab, bapitumomab, bevacizumab, bivacizumab-maytansinoid, mocantuzumab, cilizumab, certolizumab pegol, cetuximab, sifostatus, cetuximab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, ertusumab, panvituzumab, fontuzumab, gemtuzumab, gemtuzumab tuzumab, ibritumomab tiuxetansin, inotuzumab, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motuzumab, motuzumab, motuzumab, natalizumab, nivolum ... Tocilizumab, novolizumab, numazumab, orelizumab, omalizumab, palivizumab, panitumumab, pascolizumab, pegolutuzumab, pertuzumab, pertuzumab, pexelizumab, lalizumab, ranibizumab, reslizumab, retizumab, resivirizumab, rituximab, rovizumab, rulizumab, sirolizumab, cilizumab, sotuzumab, tetizumab, taduzumab, talizumab, tefezumab, tocilizumab, tolizumab, tositumomab, trastuzumab, simoleukin, tocuzumab, umalizumab, uvetuzumab, and visilizumab. 20 . The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to claim 14 , wherein the linker comprises a cleavable linker or a non-cleavable linker.

21. The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to claim 14, wherein R 4 and R 5 Each is independently hydrogen, methyl or ethyl.

22. The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to claim 14, wherein R 1 is pyrrolidinyl, piperidinyl, piperazinyl, 4-methylpiperazin-1-yl, morpholino, Y is -CH 2 -or-C 2 H 4 -, Z is -CHR-, -NR, -O- or -S-, and R is hydrogen or C 1-3 alkyl.

23. The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to claim 14, wherein the benzoselenophene compound is Compound 3 or Compound 4: [Compound 3] or [Compound 4] 24. The antibody-drug conjugate according to claim 17 or a pharmaceutically acceptable salt thereof, Wherein the tumor is a cancer, and the cancer is at least one selected from the group consisting of leukemia, uterine cancer, uterine fibroids, meningioma, lung cancer, gastrointestinal malignancies, breast cancer, ovarian cancer, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, brain cancer, sarcoma and melanoma.

25. The antibody-drug conjugate according to claim 17 or a pharmaceutically acceptable salt thereof, The tumor is a cancer, and the cancer is at least one selected from the group consisting of brain metastases, intestinal cancer, small cell lung cancer, non-small cell lung cancer, osteogenic sarcoma and Kaposi's sarcoma.